Haleon Shares Slide as Weak Growth and Analyst Downgrades Weigh

Shares in consumer health giant Haleon (LON: HLN) are nursing significant losses, having fallen 11.1% year-to-date and 15.5% over the past three months, with the stock currently trading around 333p — well below its 52-week high of 410p.

The pressure began crystallising when Haleon delivered its full-year 2025 results in late February, which revealed a mixed picture.

While net profit rose a respectable 15.6% to £1.67bn and margin expansion impressed, total reported revenues slipped approximately 2% year-on-year to £11.03bn. Crucially, organic revenue growth of just 3% missed the company’s own medium-term target of 4–6%, reflecting a softer-than-expected consumer backdrop — particularly in North America, where Sensodyne and other flagship brands faced headwinds from squeezed household budgets and demand softness in discretionary health categories.

Concerns deepened when Haleon’s Q1 2026 trading update showed organic revenue growth of only 2.2%, adding to fears that the company’s 2026 guidance of 3–5% organic growth — still below its medium-term ambition — may itself prove optimistic, especially with US tariff uncertainties potentially disrupting its supply chains and consumer pricing power.

The earnings narrative has further been undermined by a string of EPS misses. In Q3 2025, Haleon posted a 10.9% negative earnings surprise.

Analyst sentiment has deteriorated markedly in response. Rothschild & Co Redburn downgraded the stock to Neutral from Buy with a 365p target. Deutsche Bank, already bearish with a Sell rating, slashed its target to 325p from 350p. Morgan Stanley, while maintaining its Overweight stance, trimmed its target to 430p from 440p.

The consensus picture is of a fundamentally sound business — home to trusted brands including Advil, Panadol and Centrum — that is struggling to generate the organic growth momentum its valuation demands.